Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections

Barbara Rehermann, Antonio Bertoletti – 21 July 2014 – Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause a large proportion of acute and chronic liver disease worldwide. Over the past decades many immunological studies defined host immune responses that mediate spontaneous clearance of acute HBV and HCV infection. However, host immune responses are also relevant in the context of treatment‐induced clearance of chronic HBV and HCV infection.

When to perform hepatic resection for intermediate‐stage hepatocellular carcinoma

Alessandro Cucchetti, Benjamin Djulbegovic, Athanasios Tsalatsanis, Alessandro Vitale, Iztok Hozo, Fabio Piscaglia, Matteo Cescon, Giorgio Ercolani, Francesco Tuci, Umberto Cillo, Antonio Daniele Pinna – 21 July 2014 – Transcatheter arterial chemoembolization (TACE) is the first‐line therapy recommended for patients with intermediate hepatocellular carcinoma (HCC). However, in clinical practice, these patients are often referred to surgical teams to be evaluated for hepatectomy.

Subscribe to